CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 2 enrolled
Drug / intervention
Thalidomidedrug
Likely dose
Thalidomide 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02507336
NCT02507336Phase 2Completed
CompareCT.gov

Long-term Follow-up and/or Continued Thalidomide (THALOMID®) Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165

University of Miami·interventional·Posted Jul 23, 2015·Updated Aug 1, 2024

In Brief

A Phase 2 clinical trial evaluating Thalidomide for Mantle Cell Lymphoma and Non-Hodgkin's Lymphoma. Completed, enrolled 2 participants across 1 site.

Detailed Summary

The study seeks to provide long-term follow-up and/or to offer continued maintenance thalidomide (THALOMID) therapy to those patients enrolled in 20030165. Patients will be followed until withdrawal of consent, or death.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma, Non-Hodgkin's Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 23, 2015
Enrollment StartNov 24, 2015
Primary CompletionAug 2, 2023
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 10.9 years ago

Interventions

Thalidomidedrug

100-300 mg capsule taken by mouth once daily.